Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasterone for HSDD in postmenopausal women
NCT03287232Phase 3Completed
- Sponsor
- Endoceutics
- Start
- Oct 2017
- Primary completion
- Mar 2019
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
A Phase 3 trial of prasterone in hypoactive sexual desire disorder (HSDD), sponsored by Endoceutics. Started Oct 2017; status: completed.
02
Drugs
prasterone
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT03287232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287232.